Instituto Nacional do Câncer, Hospital do Câncer II, Equador St, 831, 3rd Floor - Santo Cristo, Rio de Janeiro, RJ, 22220-410, Brazil.
Med Oncol. 2018 Jan 31;35(3):20. doi: 10.1007/s12032-018-1086-7.
The treatment of endometrial cancer (EC) is challenging. There is no standard of care for patients who progressed after carboplatin and paclitaxel (CT) and all available drugs show a small response and poor long-term survival in this scenario. The objective of this study was to evaluate the efficacy and toxicity profile of palliative doxorubicin after progression to CT therapy in advanced or recurrent EC. A retrospective review of the Brazilian National Cancer Institute database between 2009 and 2013 was performed, and all patients with recurrent and advanced EC treated with palliative doxorubicin after progression on CT were included. Progression-free survival (PFS), overall survival (OS), objective response rates as well as toxicity were evaluated. A total of 33 patients were enrolled, with a median age of 65.7 years. Objective responses were documented in 12.1% (3.0% of complete responses and 9.1% of partial responses). The median PFS was 4.4 months, and the median OS was 8.1 months for patients exposed to doxorubicin. The most common adverse event was anemia observed in 60.6% of patients. This retrospective study suggests that doxorubicin has a modest activity in patients with advanced or recurrent EC after treatment with CT.
子宫内膜癌（EC）的治疗具有挑战性。对于在卡铂和紫杉醇（CT）治疗后进展的患者，尚无标准的治疗方法，并且在这种情况下，所有可用的药物的反应都很小，长期生存情况也较差。本研究的目的是评估姑息性多柔比星在 CT 治疗后进展的晚期或复发性 EC 患者中的疗效和毒性特征。对 2009 年至 2013 年巴西国家癌症研究所数据库进行了回顾性分析，并纳入了所有接受 CT 治疗后进展时接受姑息性多柔比星治疗的复发性和晚期 EC 患者。评估无进展生存期（PFS）、总生存期（OS）、客观缓解率以及毒性。共纳入 33 例患者，中位年龄为 65.7 岁。客观缓解率为 12.1%（完全缓解率为 3.0%，部分缓解率为 9.1%）。多柔比星组的中位 PFS 为 4.4 个月，中位 OS 为 8.1 个月。最常见的不良事件是贫血，有 60.6%的患者出现该不良反应。这项回顾性研究表明，多柔比星在 CT 治疗后进展的晚期或复发性 EC 患者中具有一定的活性。
